MedTrace Logo

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

NCT02943603 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2018-07-13

No results posted yet for this study

Summary

This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.

Conditions

  • Adenocarcinoma
  • Stomach Cancer

Interventions

DRUG

mFLOFOX6 + pembrolizumab

the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.

Sponsors & Collaborators

  • Weijing Sun, MD, FACP

    lead OTHER

Principal Investigators

  • Weijing Sun, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-01-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943603 on ClinicalTrials.gov